FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Clinical trials for FLT3-MUTATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new FLT3-MUTATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets tough childhood leukemia
Disease control OngoingThis study tests a drug called midostaurin, given with standard chemotherapy, for children with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). The goal is to see if the combination is safe and helps control the disease. Twenty-two children will receive the …
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:43 UTC
-
New hope for older AML patients with FLT3 mutation: triple therapy trial underway
Disease control OngoingThis study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with a fast-growing type of acute myeloid leukemia (AML) who cannot have standard chemotherapy. The goal is to find the best dose and see how well the treatment con…
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 20, 2026 12:08 UTC